NCT07714018Recruiting
Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance
Development and Analysis of Weight Loss Programs for Renal Cell Carcinoma Patients on Active Surveillance
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This clinical trial compares two different weight-loss programs, daily continuous calorie energy reduction (CER) versus (vs.) 5:2 intermittent fasting (IF), in preventing progression of kidney (renal) cancer among patients with one or more small renal masses (SRM) undergoing active surveillance (AS). Kidney cancer patients tend to have changes in metabolism that may increase body weight, but weight-loss strategies that work for best for these patients are unknown. The CER program requires a set daily limit for calories. The IF program requires fasting for 2 days a week and normal eating for the remaining 5 days. Both will include self-monitoring with interventionist feedback. This trial may help researchers determine whether the IF program works better than the CER program in improving weight loss, physical health, and/or reducing the risk of kidney cancer progression among patients with small renal masses undergoing AS
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 15 Jul 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- Roswell Park Cancer Institute
- Diseases
- Kidney cancer
- NCT number
- NCT07714018
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Nov 2026 to the primary completion date, 1 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- On weight loss medication in the past 3 months
- Bariatric surgery in the last 10 years
- Received an investigational agent within 30 days prior to enrollment
Other illness
- Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug
Age
- Less than 18 years old
Other
- Non-English speaking
- BMI \< 25 kg/m\^2
- Medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component
- Pregnant or lactating
- More than 5% body weight loss in the past 3 months
- Unwilling or unable to follow protocol requirements
Who the study is looking for
- English speaking
- SRM patient with biopsy-confirmed RCC who are initiating or already on AS
- Age 18 years or older
- Body mass index (BMI) ≥ 25 kg/m\^2
- No medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component
- No weight loss medication in the past 3 months
- Not pregnant or lactating
- No more than 5% body weight loss in the past 3 months
- No bariatric surgery in the last 10 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Roswell Park Comprehensive Cancer Center Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.